Immunovant, Inc. (IMVT) reporting calendar
Immunovant, Inc. files periodic reports with the SEC as IMVT on Nasdaq. Atlas tracks 29 filed reports for this issuer, each linked to its original EDGAR accession.
- Next window
- 28 Jul 2026 – 19 Aug 2026
- Latest report
- 10-K
- Period ended
- 31 Mar 2026
- Filed
- 20 May 2026
- Reports on record
- 29
How this window is derived. Derived from this issuer's own filing history: 9 periods at a median 91-day cadence, filed a median 39 days after period end. The SEC does not publish forward reporting dates and Atlas does not estimate one.
Open IMVT market profile
Latest filing on SEC EDGAR ↗
Biological Products, (No Diagnostic Substances) reporting datesAll Nasdaq reporting dates
Filed periodic reports
| Form | Period ended | Filed | Lag | SEC accession |
|---|---|---|---|---|
| 10-K | 31 Mar 2026 | 20 May 2026 | 50 days | 0001764013-26-000064 |
| 10-Q | 31 Dec 2025 | 6 Feb 2026 | 37 days | 0001764013-26-000011 |
| 10-Q | 30 Sep 2025 | 10 Nov 2025 | 41 days | 0001764013-25-000149 |
| 10-Q | 30 Jun 2025 | 11 Aug 2025 | 42 days | 0001764013-25-000129 |
| 10-K | 31 Mar 2025 | 29 May 2025 | 59 days | 0001764013-25-000092 |
| 10-Q | 31 Dec 2024 | 6 Feb 2025 | 37 days | 0001764013-25-000026 |
| 10-Q | 30 Sep 2024 | 7 Nov 2024 | 38 days | 0001764013-24-000184 |
| 10-Q | 30 Jun 2024 | 6 Aug 2024 | 37 days | 0001764013-24-000148 |
| 10-K | 31 Mar 2024 | 29 May 2024 | 59 days | 0001764013-24-000109 |
| 10-Q | 31 Dec 2023 | 12 Feb 2024 | 43 days | 0001764013-24-000026 |
| 10-Q | 30 Sep 2023 | 9 Nov 2023 | 40 days | 0001764013-23-000133 |
| 10-Q | 30 Jun 2023 | 10 Aug 2023 | 41 days | 0001764013-23-000092 |
| 10-K | 31 Mar 2023 | 22 May 2023 | 52 days | 0001764013-23-000065 |
| 10-Q | 31 Dec 2022 | 3 Feb 2023 | 34 days | 0001764013-23-000022 |
| 10-Q | 30 Sep 2022 | 4 Nov 2022 | 35 days | 0001764013-22-000140 |
| 10-Q | 30 Jun 2022 | 5 Aug 2022 | 36 days | 0001764013-22-000085 |
| 10-K | 31 Mar 2022 | 8 Jun 2022 | 69 days | 0001764013-22-000059 |
| 10-Q | 31 Dec 2021 | 4 Feb 2022 | 35 days | 0001764013-22-000031 |
| 10-Q | 30 Sep 2021 | 5 Nov 2021 | 36 days | 0001764013-21-000119 |
| 10-Q | 30 Jun 2021 | 9 Aug 2021 | 40 days | 0001764013-21-000079 |
| 10-K | 31 Mar 2021 | 1 Jun 2021 | 62 days | 0001764013-21-000052 |
| 10-Q | 31 Dec 2020 | 16 Feb 2021 | 47 days | 0001764013-21-000018 |
| 10-Q | 30 Sep 2020 | 12 Nov 2020 | 43 days | 0001764013-20-000063 |
| 10-Q | 30 Jun 2020 | 12 Aug 2020 | 43 days | 0001764013-20-000018 |
| 10-K | 31 Mar 2020 | 29 Jun 2020 | 90 days | 0000950123-20-006444 |
| 10-Q | 31 Dec 2019 | 14 Feb 2020 | 45 days | 0001193125-20-036661 |
| 10-Q | 30 Sep 2019 | 13 Nov 2019 | 44 days | 0001213900-19-023173 |
| 10-Q | 30 Jun 2019 | 12 Aug 2019 | 43 days | 0001213900-19-015337 |
| 10-Q | 31 Mar 2019 | 12 Jun 2019 | 73 days | 0001213900-19-010580 |
Source: SEC EDGAR company submissions for CIK 0001764013. Atlas publishes filed facts only. The SEC does not publish forward reporting dates, so no announced future date is claimed here.